App-Quantinova.ai

Single-Cell Genomics Reveals Spatial and Stage-Associated Diversity in Multiple Sclerosis

Lucas Schirmer - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

N/A

Individualized Onabotulinumtoxina Treatment for Spasticity in Multiple Sclerosis Resulted in High Patient and Clinician Satisfaction: The Aspire Study

Daniel S Bandari - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

OnabotulinumtoxinA

Precision Medicine in the MS: Current state and new biological tools

Gavin Giovannoni - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Methadone hydrochloride

Effect of Age at Puberty on Risk of Multiple Sclerosis: A Mendelian Randomization Study

Adil Harroud - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

N/A

Evaluation of No Evidence of Progression or Active Disease (NEPAD) in Patients with Relapsing Multiple Sclerosis in the OPERA I and OPERA II Trials

Laura Julian - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Multiple Sclerosis

Ocrelizumab

The Paradigms Study: A Randomized Double-Blind Trial of Fingolimod Versus Interferon β-1a in Patients with Multiple Sclerosis Aged 10 to < 18 Years

Tanuja Chitnis - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Multiple Sclerosis

Fingolimod

Durable Improvements in Relapse and Disability Outcomes over 7 Years with Alemtuzumab in CARE-MS II Patients: Results from the TOPAZ Study

Barry A Singer - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Alemtuzumab

Analysis of 6-Month Confirmed Disability Progression in RRMS Patients Treated with Subcutaneous Interferon Beta-1a

Ms. Schiffon L Wong - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Ectodermal dysplasia-syndactyly syndrome

Interferon beta-1a

Effect of Ocrelizumab on Severe Progression of Upper Extremity Impairment in Patients with Primary Progressive Multiple Sclerosis in ORATORIO

Bruno Musch - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Multiple Sclerosis

Ocrelizumab

Selective, Discontinuous Reduction of B and T Lymphocytes and NK Cells in Patients with Early, Relapsing MS after administration

Ursula Boschert - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Cladribine

Neutrophil and Monocyte Cell Numbers Remained Within Normal Limits in Patients with RRMS Treated with Cladribine Tablets 3.5 Mg/Kg (CLARITY/CLARITY EXT.)

Fernando Dangond - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Neutropenia

Cladribine

Long-Term Lymphocyte Counts in Patients with RRMS Treated with Cladribine Tablets 3.5 Mg/Kg: Total Lymphocytes, B-, and T-Cell Subsets

Fernando Dangond - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Cladribine

Effectiveness of Lymphocyte-Based Re-Treatment Criteria in Minimizing the Incidence of Severe Sustained Lymphopenia with Cladribine Tablets 3.5 mg/kg

Fernando Dangond - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lymphocytopenia

Cladribine

Distinct Effects of Obesity and Vitamin D on Risk of Multiple Sclerosis: A Mendelian Randomization Study

Adil Harroud - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Multiple Sclerosis

Ergocalciferol

Induction of GM-CSF By Cigarette Smoke in T Cells: A Potential Pathogenic Role of Smoking in Multiple Sclerosis

Mr. Mohammed Alrouji - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

GM-CSF

Long-Term Predictors of Relapse or Disability Progression in Patients with Multiple Sclerosis in the Transforms and Freedoms/Freedoms II Studies

Pavle Repovic - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Multiple Sclerosis

Fingolimod

Engaging Multiple Stakeholder Groups in the Development of Standards for Multiple Sclerosis Care: A Modified Delphi Process

Jeremy Hobart - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

N/A

Hypothesis: Multiple Sclerosis Is Caused By a Sequential Double Hit of Two Common Infections.

Patrick KA Kearns - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

N/A

Glunomab®: A Novel “Barrier-Protecting” Monoclonal Antibody Efficient in Mouse Models of EAE.

Richard Macrez - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

A UK District General Hospital experience of using High Flow Nasal Oxygen

Bilal Shoaib - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Filters

45280 Abstracts